Clinical trial J2N-MC-JZNX
A Phase 2, Open-label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Previously Received Treatment with a Covalent Bruton Tyrosine Kinase Inhibitor
| Organ | LLC |
|---|---|
| Trial status | Trial open for recruitment |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Lilly |
| EudraCT Identifier | 2024-515689-15-01 |
| Last update |